Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

NCT04278222 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Immunotherapy
Anlotinib
Toripalimab

Interventions

DRUG: Anlotinib Plus Toripalimab

Sponsor

Shanghai Changzheng Hospital